Callisto Corporate Video Presentation Focuses on Company's Anti-Cancer Drug Candidates as 2nd Clinical Trial Starts
9th Dec 2005, 20:41 GMT
Callisto Pharmaceuticals, a developer of new drug treatments in the fight against cancer and other health threats, has released a corporate video presentation outlining the Company's current lead anti-cancer drug candidates, Atiprimod and L-Annamycin.
Callisto Corporate Video Presentation Focuses on Company's Anti-Cancer Drug Candidates as 2nd Clinical Trial Starts related news:
- Callisto Details Clinical Research Progress on Proprietary Anti-Cancer Drugs and Strategic Initiatives for 2006 — Operations-Related News from StratCenter.com
- Web Alert: Callisto to Host Investor Conference Call to Discuss Developments in Anti-Cancer Drug Trials and IP Growth — Operations-Related News from StratCenter.com
- Callisto Outlines Achievements in Development of Anti-Cancer Drug Candidates and Other Recent Advances in Online Interview — Pharmaceuticals News from StratCenter.com
- Callisto initiates early-stage leukemia drug trial — Pharmaceutical Business Review Online
- Cytokinetics Announces Presentation of Ispinesib Data at San Antonio Breast Cancer Symposium — Mammography News from StratCenter.com
- Callisto Establishes Intellectual Property Dept to Expand New Drug Pipeline and Strengthen Patent Protection — Bio-Technology News from StratCenter.com
- Callisto Issues Updated Investor Fact Sheet to Reflect Latest Intellectual Property Expansion and Business Developments — StratWire - Business of Healthcare NewsFeed
- Kosan Initiates Phase II Clinical Trial of KOS-953 in Combination With Herceptin for Treatment of Metastatic Breast Cancer — Radiology News from StratCenter.com
- Race and gender affect lung cancer clinical trial participation — EurekAlert! - Medicine and Health
- Alizyme obesity drug passes clinical trial — Reuters: Shares
Latest news from StratWire - Business of Healthcare NewsFeed:
- Alliance Names New COO
- NHCAA to Award Those Who Fight and Expose the Deadly Side of Health Care Fraud
- More Than 2 mln Cancer Patients Treated with BrainLAB m3 Shaped Beam Radiosurgery
- PA's Continuing Trend Towards Total Body Reconstruction Keeps Consumers Demanding Comprehensive Direct-To-Consumer-Education (DTCE )
- Dr Farzad Yaghouti of Global Laser Vision San Diego Wins 'Best Lasik Surgeon 2006'
- 1st Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
- Medical Mutual of OH Financial Investigator Wins Top Nat'l Fraud-Fighting Award
- Intelligent Medical Objects and Bond Technologies Sign Multi-year Agreement
- M-CARE's Medicaid Plan Recognized as One of the Top Health Plans by US News & World Report/NCQA
- Fitch: MCH rates 'A-' on bonds